NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Recommendation of “Buy” by Analysts

Shares of NewAmsterdam Pharma (NASDAQ:NAMS) have received a consensus rating of “Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $33.25.

NAMS has been the topic of several analyst reports. TD Cowen assumed coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, May 15th. They issued a “buy” rating on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, July 30th.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CEO Michael H. Davidson acquired 5,000 shares of the company’s stock in a transaction dated Thursday, June 20th. The shares were bought at an average cost of $17.26 per share, with a total value of $86,300.00. Following the purchase, the chief executive officer now directly owns 204,784 shares of the company’s stock, valued at $3,534,571.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 19.50% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

Hedge funds have recently modified their holdings of the stock. Wolverine Asset Management LLC boosted its stake in NewAmsterdam Pharma by 197.2% during the 4th quarter. Wolverine Asset Management LLC now owns 8,694 shares of the company’s stock valued at $97,000 after purchasing an additional 5,769 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in NewAmsterdam Pharma by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock worth $3,359,000 after buying an additional 51,726 shares in the last quarter. Opaleye Management Inc. purchased a new position in NewAmsterdam Pharma during the 4th quarter worth $2,964,000. Yarbrough Capital LLC bought a new stake in shares of NewAmsterdam Pharma in the 1st quarter worth $567,000. Finally, Jennison Associates LLC purchased a new stake in shares of NewAmsterdam Pharma in the first quarter valued at about $22,015,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock opened at $17.02 on Monday. The business’s 50-day moving average price is $19.01 and its 200-day moving average price is $20.42. NewAmsterdam Pharma has a 12 month low of $5.63 and a 12 month high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, May 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.08). The company had revenue of $1.40 million for the quarter, compared to analyst estimates of $2.95 million. Analysts predict that NewAmsterdam Pharma will post -2.24 earnings per share for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.